Health Industries Thought Leadership

Explore our thinking

The new revenue cycle management

Read article

The true cost of transparency

PwC explores which system strategy – best-of-breed or single vendor – may best support providers in the transition to value-based reimbursement, and ultimately, what the EHR and RCM system of the future may look like.

The true cost of transparency

Read article

The true cost of transparency

Today the transparency movement is accelerating across the global life sciences landscape, with no signs of slowing.

Virtual Health: Engaging operational, clinical, and technology levers

Read article

Virtual Health: Engaging operational, clinical, and technology levers

As healthcare costs continue to grow and consumer expectations rise, health systems will need to change the way they deliver care.

Size should matter: Five ways to help healthcare systems realize the benefits of scale

Read article

Size should matter: Five ways to help healthcare systems realize the benefits of scale

As reimbursement rates decline for both public and private payors, hospitals and healthcare systems face declining revenue, pressuring them to reduce costs by 20 to 25 percent in the short term.

Harnessing insights to drive decisions

Read article

Harnessing insights to drive decisions

Given the burgeoning availability of data and rapid development of analytics, the industry is finding new approaches to leverage data and drive strategic decision-making.

The still expanding state of Medicaid in the United States

Read article

The still expanding state of Medicaid in the United States

Last year, 2014, full implementation of the Affordable Care Act powered growth in Medicaid, the government sponsored health coverage program for the low income and disabled. With over 9 million new beneficiaries, market observers questioned what year two post-ACA would bring – a tapering of the dramatic growth as coverage approached a natural ceiling or a continued upward trend as more states expanded and more Americans realized their eligibility? And, of importance for many market observers, would the unprecedented growth in private Medicaid health plans continue?

Knowledge Management: Unlocking value in pharma life sciences

Read article

Knowledge Management: Unlocking value in pharma life sciences

With the increasing relevance of data analytics, Pharmaceutical and Life Sciences executives are becoming more data-driven and discovering that effective knowledge management, especially in their QMS-governed quality, regulatory, and clinical processes, can unlock efficiencies and drive informed, timely decision making.

Xavier University & PwC pharmaceutical quality metrics white paper

Read article

Xavier University & PwC pharmaceutical quality metrics white paper

In support of FDA’s intent to allocate its resources based on risk, Xavier University and PwC launched a Metrics Initiative in August 2014 to identify product quality risk metrics linked to patient safety that could be viewed during an inspection. 

Beyond 2020: Building strategic coherence in the New Health Economy

Read article

Beyond 2020: Building strategic coherence in the New Health Economy

The competitive landscape for pharmaceutical and life sciences companies around the world is changing rapidly. We are now in the “New Health Economy” in which drug pricing pressures, scientific breakthroughs, expanding global demand for health care access, and emerging digital and analytical capabilities are pushing the health care industry toward a new ecosystem defined by collaboration, quality and consumer value. 

The FDA and industry: Recipe for collaborating in the New Health Economy

The FDA and industry: Recipe for collaborating in the New Health Economy

Read article

Innovating in the 21st century: Assessing the role of the FDA quality

Innovating in the 21st century: Assessing the role of the FDA quality

Balancing innovation and risk when developing new drugs and devices requires tradeoffs. To improve access to new treatments, the pharmaceutical and medical device industry is willing to consider regulatory reforms such as stricter post-market safety requirements.

SEC comment letter trends for healthcare providers

SEC comment letter trends for healthcare providers

Read article

SEC comment letter trends for healthcare providers

SEC comment letter trends for healthcare providers

To help you gain insight into the SEC’s current areas of interest, we analyzed comments released by the SEC staff to domestic large accelerated, accelerated and non-accelerated registrants within the healthcare provider industry during the two year period ended August 31, 2014. From this analysis, we identified the following “hot topic” areas we believe you may find useful as you prepare for the upcoming year-end reporting cycle.

Healthcare delivery of the future

Healthcare delivery of the future

Read article

Healthcare delivery of the future

PwC's Patient Digital Care Solution

How digital technology can bridge time and distance between clinicians and consumers

Top Health Industry Issues of 2016

Top Health Industry Issues of 2016

Read article

Top Health Industry Issues of 2016

Top Health Industry Issues of 2016

PwC's Top Health Industry Issues report includes feedback from 1,000 consumers regarding their point of view on several issues related to reform and their healthcare experience. Their input on many topics is presented in the report and in detail on this website.

MoneyTree: Biotech trending high

MoneyTree: Biotech trending high

Read article

MoneyTree: Biotech trending high

MoneyTree: Biotech trending high

Investments in both the biotech and medical devices industries have continued to increase year-over-year. However, investments for the two industries declined compared to the exceptionally strong last quarter, which saw record high investments in biotech.

2014 SEC comment letter trends Pharmaceutical and Life Sciences

2015 SEC comment letter trends Pharmaceutical and Life Sciences

Read article

2015 SEC comment letter trends Pharmaceutical and Life Sciences

2014 SEC comment letter trends Pharmaceutical and Life Sciences

PwC's publication provides a comprehensive analysis of recent SEC staff comments and disclosures to assist you in understanding the key trends relevant to companies in the pharmaceutical and life sciences sector.

The rise of retail health insurance exchanges

Health wearables: Early days

Read article

Health wearables: Early days

The rise of retail health insurance exchanges

In summer 2014, PwC’s Health Research Institute and Consumer Intelligence Series launched research to better understand consumers’ attitudes and behaviors toward wearable technology amid rapid growth in the health industry.

The rise of retail health insurance exchanges

The rise of retail health insurance exchanges

Read article

The rise of retail health insurance exchanges

The rise of retail health insurance exchanges

Retail health insurance marketplaces, also known as exchanges, are changing both the employer benefits environment and the health insurance business.

PwC's Patient Digital Care Solution

PwC's Patient Digital Care Solution

Read article

PwC's Patient Digital Care Solution

PwC's Patient Digital Care Solution

PwC leveraged its experience in working with healthcare providers and in consumer experience to develop a digital solution—combined with our consulting services—that helps address the complex needs of today’s healthcare providers. PwC’s Patient Digital Care solution embraces the cloud and the Salesforce1 Platform to enable providers to enhance connections with their patients throughout the treatment cycle.

Medicaid 2.0: Health system have and have nots

Medicaid 2.0: Health system have and have nots

Read article

Medicaid 2.0: Health system have and have nots

Medicaid 2.0: Health system have and have nots

Medicaid expansion under the Affordable Care Act has delivered higher volumes and increased revenue to providers across the 26 states and the District of Columbia that expanded the program, while dramatically reducing the amount of care that goes unpaid. Hospitals in states that did not expand have seen the opposite.

Health Industry Executive Advisory Board on Privacy and Security highlights

Health Industry Executive Advisory Board on Privacy and Security highlights

Read article

Health Industry Executive Advisory Board on Privacy and Security highlights

Health Industry Executive Advisory Board on Privacy and Security highlights

In June 2014, representatives of the payer, provider, and pharmaceutical industries as well as four representatives of federal regulatory agencies came together in Washington, DC. to discuss data access and use as well as the challenges of maintaining privacy and security as information moves across the healthcare ecosystem.

Pharmaceutical and Life Sciences Deals Insights Quarterly Q2 2014

Health Services Deals Insights

Read article

Health Services Deals Insights

Pharmaceutical and Life Sciences Deals Insights Quarterly Q2 2014

2015 presented continued increases in deal volume across the vast majority of sectors when compared to 2014. Almost every sector experienced growth in either value or volume in transactions especially the healthcare sector.

Pharmaceutical and Life Sciences Deals Insights Quarterly Q2 2014

Pharmaceutical and Life Sciences Deals Insights Quarterly

Read article

Pharmaceutical and Life Sciences Deals Insights Quarterly

Pharmaceutical and Life Sciences Deals Insights Quarterly Q2 2014

We bring you PwC’s perspective on deal activity in the pharmaceutical and life sciences industry. Each quarterly publication now features two sections that highlight deal activity and insights from a global view:

  • Market update: A summary of M&A deals and trends for the quarter.
  • Strategy corner: A feature offering tips and insights on various aspects of deal making.

Refer also to our previous publications for insights into executing deals in specific geographic markets, and explorations of various aspects of successful transactions.

Hispanics: A growing force in the New Health Economy

Hispanics: A growing force in the New Health Economy

Learn more

Hispanics: A growing force in the New Health Economy

Hispanics: A growing force in the New Health Economy

Hispanics represent unparalleled growth opportunities for businesses aiming to succeed in the New Health Economy. But, if healthcare companies fail to “speak their language,” they will miss opportunities to capture the fastest growing demographic in the US and gain their customer loyalty.

QMS 3.0: The next generation of quality management systems

QMS 3.0: The next generation of quality management systems

Read article

QMS 3.0: The next generation of quality management systems

QMS 3.0: The next generation of quality management systems

In this age of intense scientific discovery, life sciences companies are becoming increasingly complex. Biopharmaceutical and medical device businesses are developing more complicated products in the form of bio-similars, implantables, combination products, and others. These companies are operating across multiple industry segments (pharmaceuticals, diagnostics, medical devices, OTC, etc.), and they are entering varied emerging markets. In this environment, current quality management systems (QMS) have not kept pace with a growing variety of products and technological complexity. A new QMS framework is needed to inject heightened effectiveness and efficiency into the industry quality processes.

California Biomedical Industry Report 2015

California Biomedical Industry Report 2015

Learn more

California Biomedical Industry Report 2015

California Biomedical Industry Report 2015

California holds a unique position in the worldwide life sciences community, producing some of the world’s most innovative therapies and diagnostics. In turn, these corporations have made the state’s life sciences industry an economic juggernaut. Our annual report, in collaboration with the California Healthcare Institute, looks at how the state works with companies to nurture the biomedical industry.

MoneyTree: Biotech soars to record high

MoneyTree: Biotech soars to record high

Read article

MoneyTree: Biotech soars to record high

MoneyTree: Biotech soars to record high

Biotech soars to record high: Investment in biotechnology was the highest since the start of the MoneyTree data series in 1995. Biotech and medical devices industries both see year-over-year double-digit growth in investments.

Phase 2: The next generation of HIPAA audits

Phase 2: The next generation of HIPAA audits

Learn more.

Phase 2: The next generation of HIPAA audits

Phase 2: The next generation of HIPAA audits

Earlier this year, the Office for Civil Rights (OCR) announced the implementation of a “Phase 2” audit program to begin in fall 2014 based on the findings of the 2012 pilot privacy and security audits of payers and providers. In Phase 2, the OCR will conduct audits of HIPAA-covered entities, with audits for business associates anticipated to begin in 2015. For more information about the impact and how best to prepare download and read our four page brief which includes highlights, additional background, analysis and FAQs for planning.

Data driven progress: As informatics evolves, clinicians find ways to stay ahead of illness and revamp care delivery

Data driven progress: As informatics evolves, clinicians find ways to stay ahead of illness and revamp care delivery

Read article

Data driven progress: As informatics evolves, clinicians find ways to stay ahead of illness and revamp care delivery

Data driven progress: As informatics evolves, clinicians find ways to stay ahead of illness and revamp care delivery

PwC’s Health Industries practice brought together a panel of three specialists from the clinical, technical and operational side of healthcare during the Healthcare Information and Management Systems Society (HIMSS) annual conference to discuss and share best practices in medical informatics. While the participants varied in their pace and depth of commitment to informatics, all agreed that the potential of technology to positively impact patient care and coordination is profound.

MoneyTree: Biotech deals rising

MoneyTree: Biotech deals rising

Read article

MoneyTree: Biotech deals rising

MoneyTree: Biotech deals rising

Investments increased year over year for biotech as well as medical devices. The average deal size for early stage medical device investments was the highest since 1995. However, life sciences investments underperformed total venture capital investments and are now at the lowest proportion of total investments since 2001.

Health Services Deals Insights

Health Services Deals Insights

Learn more

Health Services Deals Insights

Health Services Deals Insights

2015 presented continued increases in deal volume across the vast majority of sectors when compared to 2014. Almost every sector experienced growth in either value or volume in transactions especially the healthcare sector.

Pharmaceutical and Life Sciences Deals Insights Quarterly

Pharmaceutical and Life Sciences Deals Insights Quarterly

Learn more

Pharmaceutical and Life Sciences Deals Insights Quarterly

Pharmaceutical and Life Sciences Deals Insights Quarterly

Deal volume and value increase in the quarter while fundamentals and pending deals point to potential for heightened activity in the fourth quarter of 2013. Total deal volume increased approximately 10% during the third quarter of 2013 in comparison with the second quarter of 2013, while declining by approximately the same amount relative to the third quarter of 2012. Deal value increased by nearly 50% over the previous quarter while declining approximately 15% relative to the third quarter of 2012. The increase in the third quarter owes primarily to two large transactions in the medical device segment.

Why Customer Centricity matters

Why Customer Centricity matters

Learn more.

Why Customer Centricity matters

Why Customer Centricity matters

Since healthcare is perceived as a necessity for all consumers, providing a personalized customer experience has not historically been a focus for healthcare executives. Despite this, several converging forces are now driving them to re-evaluate their priorities.

Unique Devices Identification System: Practical perspectives on implementation and compliance readiness

Unique Devices Identification System: Practical perspectives on implementation and compliance readiness

Learn more

Unique Devices Identification System: Practical perspectives on implementation and compliance readiness

Unique Devices Identification System: Practical perspectives on implementation and compliance readiness

In our experience to date, manufacturers have been more focused on device labeling and GUDID reporting than on conforming amendments. This may represent a blind spot for some manufacturers.

Pharmaceutical and Life Sciences: 2013 SEC comment letter trends

Pharmaceutical and Life Sciences: 2015 SEC comment letter trends

Read article

Pharmaceutical and Life Sciences: 2015 SEC comment letter trends

Pharmaceutical and Life Sciences: 2013 SEC comment letter trends

PwC's publication provides a comprehensive analysis of recent SEC staff comments and disclosures to assist you in understanding the key trends relevant to companies in the pharmaceutical and life sciences sector.

Healthcare’s new entrant: Who will be the industry’s Amazon.com

Healthcare’s new entrant: Who will be the industry’s Amazon.com

Read article

Healthcare’s new entrant: Who will be the industry’s Amazon.com

Healthcare’s new entrants: Who will be the industry’s Amazon.com?

The health sector's center of gravity is shifting toward consumers and new tech-savvy players are moving fast to capitalize on the change. These new entrants are poised to shake up the industry, drawing billions of dollars in revenue from traditional healthcare organizations while building lucrative new markets in the burgeoning New Health Economy.

Rx Marketplace Quarterly Newsletter

Rx Marketplace Quarterly Newsletter

Read article

Rx Marketplace Quarterly Newsletter

Rx Marketplace Quarterly Newsletter

The PwC Rx Marketplace Quarterly features a wide range of financial reporting developments, accounting and tax developments, regulatory updates and general industry trends impacting the pharmaceutical and life sciences industry.

Top health industry issues for life sciences in 2014

Top health industry issues for life sciences in 2014

Learn more

Top health industry issues for life sciences in 2014

Top health industry issues for life sciences in 2014

Michael Swanick, global leader of PwC's pharmaceutical and life sciences practice has shared findings based on our Health Research Institute's annual Top health industry issues report to address which issues we believe will directly impact the pharma, biotech and device manufacturers in 2014 (in no particular order are): Corporate venture capital, clinical research methods, counterfeit drugs and the new regulations intended to eliminate them as well as social, mobile, analytics and cloud technologies that are changing existing business models.

Serialization and ePedigree PwC perspectives for manufacturers

Serialization and ePedigree PwC perspectives for manufacturers

Learn more

Serialization and ePedigree PwC perspectives for manufacturers

Serialization and ePedigree PwC perspectives for manufacturers

Pharmaceutical and biotech manufacturers are working to comply with serialization and drug security legislation from around the globe. The intent of the US Drug Quality and Security Act, and the EU directive on serialization are US drug supply chain security and EU serialization.

EFPIA and Global Transparency Requirements

EFPIA and Global Transparency Requirements

Learn more

EFPIA and Global Transparency Requirements

EFPIA and Global Transparency Requirements

Implementing an aggregate spend program in a global marketplace. Treating industry codes, laws, and regulations without considering the broader global transparency landscape, is not an option if companies intend to develop smart transparency approaches and supporting models that more efficiently and effectively address what is required of them. Many of the regulations and requirements imposed on pharmaceutical and life sciences companies have commonalities that create opportunities for businesses to incorporate process efficiencies and economies of scale when developing their transparency strategies.

Health Industry Executive Advisory Board on Privacy and Security highlights

Health Industry Executive Advisory Board on Privacy and Security highlights

Read article

Health Industry Executive Advisory Board on Privacy and Security highlights

Health Industry Executive Advisory Board on Privacy and Security highlights

February 2014

In June 2014, representatives of the payer, provider, and pharmaceutical industries as well as four representatives of federal regulatory agencies came together in Washington, DC. to discuss data access and use as well as the challenges of maintaining privacy and security as information moves across the healthcare ecosystem

180 Health Forum Highlights: The changing faces of healthcare

180 Health Forum Highlights: The changing faces of healthcare

Read article

180 Health Forum Highlights: The changing faces of healthcare

180 Health Forum Highlights: The changing faces of healthcare

January 2014

More than 100 thought leaders and CxO's from across all sectors of the US health industries, along with recent entrants, gathered to explore the new health economy that is emerging in the United States at PwC's 180 Health Forum. Since its inception, the Forum has provided a venue for challenging the status quo by bringing in some of the most provocative thinkers in the healthcare arena to share their insights with our clients. Our Forum Highlights provide an overview of the conversations that occurred at the 2013 180 Health Forum.

Healthcare provider 2013 SEC comment letter trends

Healthcare provider 2013 SEC comment letter trends

Read article

Healthcare provider 2013 SEC comment letter trends

Healthcare provider 2013 SEC comment letter trends

December 2013

We are pleased to offer you the inaugural edition of Stay informed—Healthcare provider 2013 SEC comment letter trends. This document analyzes the key areas where registrants in the healthcare provider industry received the most number of comments from the SEC during the three year period ended September 30, 2013. It also provides a discussion of the related guidance as well as sample comment letters on each area. Included for your information are some best practices on how to effectively respond to comments received and a summary of the SEC’s filing review process.

Partnering for change: Report on the 2013 annual CBO consortium

Partnering for change: Report on the 2013 annual CBO consortium

Read article

Partnering for change: Report on the 2013 annual CBO consortium

Partnering for change: Report on the 2013 annual CBO consortium

Summer 2012

The Central Business Office (CBO) Consortium is a gathering of the revenue cycle leaders from large healthcare systems across the country who come together each year to share information that can help them enhance their revenue cycle performance.

Top health industry issues of 2014

Top health industry issues of 2014

Learn more

Top health industry issues of 2014

Top health industry issues of 2014

A new health economy takes shape

California Biomedical Industry, 2014 Report

California Biomedical Industry, 2014 Report

Read article

California Biomedical Industry, 2014 Report

California Biomedical Industry, 2014 Report

California holds a unique position in the worldwide life sciences community, producing some of the world’s most innovative therapies and diagnostics. In turn, these corporations have made the state’s life sciences industry an economic juggernaut. Our annual report, in collaboration with the California Healthcare Institute, looks at how the state works with companies to nurture the biomedical industry

MoneyTree Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

MoneyTree Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

Read article

MoneyTree Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

US GAAP: Issues and solutions for pharmaceuticals and life sciences industry

While a slowdown in funding occurred in life sciences, venture funding for all industries increased sharply, with 1,005 deals driving revenues of $7.8 billion in the third quarter, an increase of 17% in value and 7% in the number of deals year over year.

Q3 2013 US Health Services Deals Insights

Q3 2013 US Health Services Deals Insights

Learn more

Q3 2013 US Health Services Deals Insights

Q2 2013 US Health Services Deals Insights

The third quarter of 2013 realized a slight uptick over the prior two quarters in the volume of healthcare service deals with 138 total transactions. The value of the deals announced in the third quarter, $15.8 billion, was up 35% over the second quarter. However, in both volume and value the year-to-date period for 2013 continues to lag the same period in 2012 with volume down 4.6% and value down 25%.

US GAAP: Issues and solutions for pharmaceuticals and life sciences industry

US GAAP: Issues and solutions for pharmaceuticals and life sciences industry

Read article

US GAAP: Issues and solutions for pharmaceuticals and life sciences industry

US GAAP: Issues and solutions for pharmaceuticals and life sciences industry

Internet, Communications and Publishing sub-sectors saw increased deal activity, contributing to the 9% growth in announced deals for the 3 quarters ended 2013 versus prior year. In addition to deal trends for the year to date, a deeper look at one sub-sector -- telecom operations -- and the deal opportunities abounding as telecom companies look to improve network operations and spectrum efficiency.

A Conversation with Mike Swanick, PwC

A Conversation with Mike Swanick, PwC

Learn more

A Conversation with Mike Swanick, PwC

A Conversation with Mike Swanick, PwC

The November / December issue of Pharmaceutical Commerce features PwC's Michael Swanick, Global and US practice leader for pharmaceuticals and life sciences on their cover. In the feature article Michael discusses national and international issues affecting the pharmaceutical and life sciences industry.

Customer experience in the pharmaceutical sector

Customer experience in the pharmaceutical sector

Learn more

Customer experience in the pharmaceutical sector

Customer experience in the pharmaceutical sector

As patients exert greater control over their healthcare, drug makers need to master the complexities of consumer behavior. Consumers are willing to offer feedback that informs who they are, how they behave and how existing biases impact their behavior. Drug makers that tap into this feedback will reach a new level of success.

Medical Technology Company Innovation Scorecard

Medical Technology Company Innovation Scorecard

Read article

Medical Technology Company Innovation Scorecard

Medical Technology Company Innovation Scorecard

Medtech companies prepare for an innovation makeover

US GAAP: Issues and solutions for the medical technology industry

US GAAP: Issues and solutions for the medical technology industry

Learn more

US GAAP: Issues and solutions for the medical technology industry

US GAAP: Issues and solutions for the medical technology industry

This publication highlights factors the medical technology industry should consider and provides guidance on the most pertinent accounting solutions under US GAAP. The solutions presented are meant to provide a framework for determining the appropriate accounting answer for general solutions.

Spotlight Lease Accounting: Transformational Change

Spotlight Lease Accounting: Transformational Change

Learn more

Spotlight Lease Accounting: Transformational Change

Spotlight Lease Accounting: Transformational Change

Included in this brief are next steps organizations should consider as well as an FAQs section and key contacts you may reach out to for additional follow up.

Five Strategies for Improving Performance of Academic Medical Centers

Five Strategies for Improving Performance of Academic Medical Centers

Learn more

Five Strategies for Improving Performance of Academic Medical Centers

Five Strategies for Improving Performance of Academic Medical Centers

Academic medical centers should research and embrace new approaches to financing, operations, and governance to become more cost-efficient and profitable in an era of reform.

Medical Cost Trend: Behind The Numbers 2014

Medical Cost Trend: Behind The Numbers 2014

Learn more

Medical Cost Trend: Behind The Numbers 2014

Medical Cost Trend: Behind The Numbers 2014

Aggressive and creative steps by employers, new venues and models for delivering care, and elements of the Affordable Care Act (ACA) are expected to exert continued downward pressure on the health sector

MoneyTree<sup>TM</sup> Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

MoneyTreeTM Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

Learn more

MoneyTreeTM Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

MoneyTree<sup>TM</sup> Report from PricewaterhouseCoopers (PwC) LLP and the National Venture Capital Association (NVCA)

We bring you a quarterly publication based on US venture capital funding for the life sciences sector. The MoneyTree report is produced by PwC and The National Venture Capital Association (NVCA)*. Each quarterly contains the following sections: life sciences deals by quarter, stages, regional funding trends and a venture capital outlook. We also break down the life sciences sector into its subsegments, including biotech and medical device, to compare funding and investment trends by quarter.

Scoring healthcare: Navigating customer experience ratings

Scoring healthcare: Navigating customer experience ratings

Learn more

Scoring healthcare: Navigating customer experience ratings

Scoring healthcare: Navigating customer experience ratings

PwC's insights on the impact of the ratings culture on healthcare

Solving the talent equation for health IT

Solving the talent equation for health IT

Learn more

Solving the talent equation for health IT

Solving the talent equation for health IT

Top healthcare executives are revisiting talent strategies to overcome technology and skill availability pressures.

Emerging markets growth: The critical role of operations in driving competitive advantage

Emerging markets growth: The critical role of operations in driving competitive advantage

Learn more

Emerging markets growth: The critical role of operations in driving competitive advantage

Emerging markets growth: The critical role of operations in driving competitive advantage

Biopharmaceutical companies are expanding into emerging markets, sometimes without involving supply chain operations. The operational function (operations) should play a strategic role in emerging market expansion planning.

Risk-based monitoring: Reduce clinical trial costs while protecting safety and quality

Risk-based monitoring: Reduce clinical trial costs while protecting safety and quality

Learn more

Risk-based monitoring: Reduce clinical trial costs while protecting safety and quality

Risk-based monitoring: Reduce clinical trial costs while protecting safety and quality

The demand for higher value from pharmaceuticals and medical devices is increasing. Risk-based monitoring can reduce the development time of safe and effective products at lower cost.

How to respond to the Final Omnibus HIPAA Rule

How to respond to the Final Omnibus HIPAA Rule

Learn more

How to respond to the Final Omnibus HIPAA Rule

How to respond to the Final Omnibus HIPAA Rule

The Final HIPAA Omnibus Rule calls for changes to privacy and security requirements that healthcare organizations should address, especially where current practices and processes could be less effective and expensive to build and maintain.

CMS shines light on Transparency Final Rule: Insights and impact

CMS shines light on Transparency Final Rule: Insights and impact

Learn more